Monivent (MONI) Q3 2025 earnings summary

Executive summary

• Focus on ongoing regulatory processes to enable a global distribution agreement with a leading neonatal care partner and joint expansion into broader markets.

• Product adaptations and regulatory work for Neo100 have led to delays, impacting sales and requiring prioritization of critical activities due to limited resources.

• Participation in the jENS congress generated significant interest and new leads for potential customers.

Financial highlights

• Net sales for Q3 2025 were 160 KSEK, down from 227 KSEK in Q3 2024; for Jan–Sep 2025, net sales were 1,005 KSEK, down from 1,451 KSEK year-over-year.

• Operating costs for Q3 2025 were 3,046 KSEK (up from 2,498 KSEK); for Jan–Sep 2025, 9,733 KSEK (virtually unchanged from 9,702 KSEK).

• EBIT for Q3 2025 was -2,376 KSEK (Q3 2024: -2,271 KSEK); for Jan–Sep 2025, -6,695 KSEK (improved from -8,238 KSEK).

• Cash and cash equivalents at period end were 2,779 KSEK; equity ratio was 32%.

• Earnings per share for Jan–Sep 2025 were -0.12 SEK, improved from -0.40 SEK year-over-year.

Outlook and guidance

• Regulatory work for MDR and FDA submissions is ongoing, with delays due to resource constraints; completion of technical documentation for MDR is imminent.

• Bridge loan secures liquidity through Q1 2026; long-term financing discussions have been initiated.